T-cell receptor determinants of response to chemoradiation in locally-advanced HPV16-driven malignancies.

T-cell receptor anal cancer cervical cancer head and neck cancer human papillomavirus radiotherapy

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 19 09 2023
accepted: 28 11 2023
medline: 18 1 2024
pubmed: 18 1 2024
entrez: 18 1 2024
Statut: epublish

Résumé

The effect of chemoradiation on the anti-cancer immune response is being increasingly acknowledged; however, its clinical implications in treatment responses are yet to be fully understood. Human papillomavirus (HPV)-driven malignancies express viral oncogenic proteins which may serve as tumor-specific antigens and represent ideal candidates for monitoring the peripheral T-cell receptor (TCR) changes secondary to chemoradiotherapy (CRT). We performed intra-tumoral and pre- and post-treatment peripheral TCR sequencing in a cohort of patients with locally-advanced HPV16-positive cancers treated with CRT. An in silico computational pipeline was used to cluster TCR repertoire based on epitope-specificity and to predict affinity between these clusters and HPV16-derived epitopes. Intra-tumoral repertoire diversity, intra-tumoral and post-treatment peripheral CDR3β similarity clustering were predictive of response. In responders, CRT triggered an increase peripheral TCR clonality and clonal relatedness. Post-treatment expansion of baseline peripheral dominant TCRs was associated with response. Responders showed more baseline clustered structures of TCRs maintained post-treatment and displayed significantly more maintained clustered structures. When applying clustering by TCR-specificity methods, responders displayed a higher proportion of intra-tumoral TCRs predicted to recognise HPV16 peptides. Baseline TCR characteristics and changes in the peripheral T-cell clones triggered by CRT are associated with treatment outcome. Maintenance and boosting of pre-existing clonotypes are key elements of an effective anti-cancer immune response driven by CRT, supporting a paradigm in which the immune system plays a central role in the success of CRT in current standard-of-care protocols.

Sections du résumé

Background UNASSIGNED
The effect of chemoradiation on the anti-cancer immune response is being increasingly acknowledged; however, its clinical implications in treatment responses are yet to be fully understood. Human papillomavirus (HPV)-driven malignancies express viral oncogenic proteins which may serve as tumor-specific antigens and represent ideal candidates for monitoring the peripheral T-cell receptor (TCR) changes secondary to chemoradiotherapy (CRT).
Methods UNASSIGNED
We performed intra-tumoral and pre- and post-treatment peripheral TCR sequencing in a cohort of patients with locally-advanced HPV16-positive cancers treated with CRT. An in silico computational pipeline was used to cluster TCR repertoire based on epitope-specificity and to predict affinity between these clusters and HPV16-derived epitopes.
Results UNASSIGNED
Intra-tumoral repertoire diversity, intra-tumoral and post-treatment peripheral CDR3β similarity clustering were predictive of response. In responders, CRT triggered an increase peripheral TCR clonality and clonal relatedness. Post-treatment expansion of baseline peripheral dominant TCRs was associated with response. Responders showed more baseline clustered structures of TCRs maintained post-treatment and displayed significantly more maintained clustered structures. When applying clustering by TCR-specificity methods, responders displayed a higher proportion of intra-tumoral TCRs predicted to recognise HPV16 peptides.
Conclusions UNASSIGNED
Baseline TCR characteristics and changes in the peripheral T-cell clones triggered by CRT are associated with treatment outcome. Maintenance and boosting of pre-existing clonotypes are key elements of an effective anti-cancer immune response driven by CRT, supporting a paradigm in which the immune system plays a central role in the success of CRT in current standard-of-care protocols.

Identifiants

pubmed: 38234396
doi: 10.3389/fonc.2023.1296948
pmc: PMC10791873
doi:

Banques de données

figshare
['10.6084/m9.figshare.6025748.v1']

Types de publication

Journal Article

Langues

eng

Pagination

1296948

Informations de copyright

Copyright © 2024 Nenclares, Larkeryd, Manodoro, Lee, Lalondrelle, Gilbert, Punta, O’Leary, Rullan, Sadanandam, Chain, Melcher, Harrington and Bhide.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Pablo Nenclares (P)

Radiotherapy and Imaging Division, The Institute of Cancer Research, London, United Kingdom.
Head and Neck Unit, The Royal Marsden Hospital, London, United Kingdom.

Adrian Larkeryd (A)

Bioinformatics Unit, The Centre for Translational Immunotherapy, The Institute of Cancer Research, London, United Kingdom.

Floriana Manodoro (F)

Genomics Facility, The Institute of Cancer Research, London, United Kingdom.

Jen Y Lee (JY)

Radiotherapy and Imaging Division, The Institute of Cancer Research, London, United Kingdom.

Susan Lalondrelle (S)

Radiotherapy and Imaging Division, The Institute of Cancer Research, London, United Kingdom.

Duncan C Gilbert (DC)

Sussex Cancer Centre, University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom.

Marco Punta (M)

Unit of Immunogenetic, Leukemia Genomics and Immunobiology, IRCCS Ospedale San Raffaele, Milan, Italy.

Ben O'Leary (B)

Radiotherapy and Imaging Division, The Institute of Cancer Research, London, United Kingdom.
Head and Neck Unit, The Royal Marsden Hospital, London, United Kingdom.

Antonio Rullan (A)

Radiotherapy and Imaging Division, The Institute of Cancer Research, London, United Kingdom.
Head and Neck Unit, The Royal Marsden Hospital, London, United Kingdom.

Anguraj Sadanandam (A)

Systems and Precision Cancer Medicine Team, The Institute of Cancer Research, London, United Kingdom.

Benny Chain (B)

Division of Infection and Immunity, University College London, London, United Kingdom.

Alan Melcher (A)

Radiotherapy and Imaging Division, The Institute of Cancer Research, London, United Kingdom.

Kevin J Harrington (KJ)

Radiotherapy and Imaging Division, The Institute of Cancer Research, London, United Kingdom.
Head and Neck Unit, The Royal Marsden Hospital, London, United Kingdom.

Shreerang A Bhide (SA)

Radiotherapy and Imaging Division, The Institute of Cancer Research, London, United Kingdom.
Head and Neck Unit, The Royal Marsden Hospital, London, United Kingdom.

Classifications MeSH